Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | Arthritis Research & Therapy

Figure 2

From: Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis

Figure 2

Oral administration of STA-5326 reduces the severity of experimental autoimmune uveoretinitis (EAU) by clinical and histopathological analysis. (a) Clinical score of EAU in STA-5326-treated or vehicle-treated mice. Immunized mice were treated with 5 mg/kg or 20 mg/kg STA-5326 or vehicle from day 0 to day 14 after immunization. EAU findings were evaluated on day 14 and day 18 after immunization. (b) Histopathological images of eyes from STA-5326-treated or vehicle-treated mice. Eyes enucleated on day 18 after immunization from STA-5326-treated or vehicle-treated mice were examined. Magnification ×400. (c) Histopathological score of EAU in STA-5326-treated or vehicle-treated mice. Each point on the graph represents the clinical or pathological score of one mouse. Each bar on the graph represents the average clinical or histopathological score for each group. Statistical analysis was performed by Mann-Whitney U test.

Back to article page